broad-spectrum antiviral targeting entry of enveloped viruses
We describe an antiviral small molecule, LJ001, effective against numerous enveloped viruses including Influenza A, filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, and HIV-1. In sharp contrast, the compound had no effect on the infection of nonenveloped viruses. I...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 107; no. 7; pp. 3157 - 3162 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
16.02.2010
National Acad Sciences |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | We describe an antiviral small molecule, LJ001, effective against numerous enveloped viruses including Influenza A, filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, and HIV-1. In sharp contrast, the compound had no effect on the infection of nonenveloped viruses. In vitro and in vivo assays showed no overt toxicity. LJ001 specifically intercalated into viral membranes, irreversibly inactivated virions while leaving functionally intact envelope proteins, and inhibited viral entry at a step after virus binding but before virus-cell fusion. LJ001 pretreatment also prevented virus-induced mortality from Ebola and Rift Valley fever viruses. Structure-activity relationship analyses of LJ001, a rhodanine derivative, implicated both the polar and nonpolar ends of LJ001 in its antiviral activity. LJ001 specifically inhibited virus-cell but not cell-cell fusion, and further studies with lipid biosynthesis inhibitors indicated that LJ001 exploits the therapeutic window that exists between static viral membranes and biogenic cellular membranes with reparative capacity. In sum, our data reveal a class of broad-spectrum antivirals effective against enveloped viruses that target the viral lipid membrane and compromises its ability to mediate virus-cell fusion. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 Edited by Peter Palese, Mount Sinai School of Medicine, New York, NY, and approved December 29, 2009 (received for review August 24, 2009) 1A.N.F., T.Z., and Z.A.-A. contributed equally to this work. Author contributions: M.C.W., A.N.F., P.K., A.D., A.M., L.E.H., S.P.W., M.R.H., M.E.J., and B.L. designed research; M.C.W., A.N.F., Z.A.-A., A.G., P.W.H., J.L., N.F.W., A.Q.F., H.C.A., M.P., J.P.M., S.E.W., S.C., V.F., K.F.F., and M.R.H. performed research; M.C.W., A.N.F., T.Z., Z.A.-A., J.L., A.N.H., R.D., K.F.F., M.R.H., and M.E.J. contributed new reagents/analytic tools; M.C.W., A.N.F., Z.A.-A., A.G., P.W.H., J.L., N.F.W., A.Q.F., H.C.A., J.P.M., O.A.N., K.F.F., M.R.H., M.E.J., and B.L. analyzed data; and M.C.W., M.R.H., M.E.J., and B.L. wrote the paper. 2Present address: Department of Food Science and Technology, The Ohio State University, Columbus, OH 43210. |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.0909587107 |